News & Updates
Filter by Specialty:
Rapid childhood growth rate tied to elevated risk of islet autoimmunity, T1D development
Children who grow in height fast appears to have a higher risk of islet autoimmunity (IAA) and rapid progression to type 1 diabetes (T1D), a study has found.
Rapid childhood growth rate tied to elevated risk of islet autoimmunity, T1D development
21 Jun 2022
Normal weight obesity in adolescents tied to cardiometabolic risk
Adolescents with normal weight obesity (NMO) may present with several cardiometabolic risk factors, putting them at greater risk of developing vascular events or diabetes, suggests a recent study.
Normal weight obesity in adolescents tied to cardiometabolic risk
21 Jun 2022
How effective were oral antivirals during HK’s Omicron BA.2 wave?
A real-world study during Hong Kong’s Omicron BA.2 wave showed that both molnupiravir and nirmatrelvir/ritonavir effectively lowered the risks of disease progression and all-cause mortality in hospitalized COVID-19 patients not requiring oxygen supplementation on admission. However, mortality risk reduction was larger with nirmatrelvir/ritonavir vs molnupiravir.
How effective were oral antivirals during HK’s Omicron BA.2 wave?
21 Jun 2022
Nintedanib falls short in bladder cancer trial
In the phase II NEOBLADE* trial, the addition of the multikinase** inhibitor nintedanib to neoadjuvant chemotherapy (CT) consisting of gemcitabine and cisplatin failed to improve pathological complete response (pCR) and progression-free survival (PFS) in individuals with locally advanced muscle-invasive bladder cancer (MIBC).
Nintedanib falls short in bladder cancer trial
21 Jun 2022
Ceritinib shows therapeutic potential in ALK-positive nonsmall cell lung cancer
The anaplastic lymphoma kinase (ALK) inhibitor ceritinib delivers favourable antitumour activity in ALK-mutated nonsmall cell lung cancer (NSCLC) patients with active brain metastases and/or leptomeningeal disease, according to the phase II ASCEND-7 trial.
